Loxo Oncology is dedicated to developing highly selective medicines for patients with genetically defined cancers. The company’s approach is based on two scientific trends: the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building highly selective inhibitors against single targets in the cancer cell.